The human genome project: Benefits and risks to society

Drug Information Journal

Volumn 33, Issue 3, 1999, Pages 729-735

  Wattanapitayakul, Suvara ^a   Schommer, Jon C ^b  

^a OHIO STATE UNIVERSITY   (United States)

^b NONE

Author keywords

Human genome project; Public policy

Indexed keywords

DNA;

GENE TECHNOLOGY; GENOME; HUMAN; MEDICAL GENETICS; PHARMACOGENETICS; POLICY; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS; SOCIAL ASPECT; SOCIETY;

EID: 0032772858     PISSN: 00928615     EISSN: None     Source Type: Journal    
DOI: 10.1177/009286159903300310     Document Type: Review

References (27)

1. Fink L, Collins FS. The human genome project: View from the National Institutes of Health. J Am Med Wom Assoc. 1997;52(1):4-7,15.
2. Cantor CR. A brief sketch of the Human Genome Project and its implications for pharmaceutical technology. Pharmaceut Tech. 1993;17:22,24,26.
3. The Human Genome Project. Revised 5-year research goals of the U.S. Human Genome Project. Human Genome News. 1993;5(4):1-5.
4. The Human Genome Project. Technology transfer -Commercializing genome resource. Human Genome News. 1995;7(3-4):15.
5. Kadlec JV, McPherson RA. Ethical issues in screening and testing for genetic diseases. Clin Lab Med. 1995;15(4):989-999.
6. Ellsworth DL, Hallman DM, Boerwinkle E. Impact of the Human Genome Project of epidemiologic research. Epidermiologic Rev. 1997;19(1):3-13.
7. Scriver CR. Genetic screening, testing and treatment: How far can we go? J Inher Metab Dis. 1996;19: 401-411.
8. Olopade OI. The Human Genome Project and breast cancer. Women's Health Issues. 1997;7(4):209-214.
9. Mansfield BK. The Genome Project and the Pharmaceutical Industry. Human Genome News. 1990;2(4):1.
10. Kelloff GJ, Hawk ET, Karp JE, Crowell JA, et al. Progress in clinical chemoprevention. Sem Oncology. 1997;24(2):241-252.
11. Kalow W. Pharmacogenetics: Its place in medicine and biology. J Pharmacy Practice. 1992;6:312-316.
12. Hildebrand CE, Stallings RL, Torney DC, Fickett JW, et al. Human genome mapping and sequencing: Applications in Pharmaceutical Science. In: Pezzuto JM, Johnson ME, Manzsse HR, Ed. Biotechnology and Pharmacy. New York: Chapman & Hall; 1993.
13. Tucker GT. Clinical implications of genetic polymorphism in drug metabolism. J Pharm Pharmacol. 1994;46(Suppl 1):417-424.
14. Meyer UA. The molecular basis of genetic polymorphisms of drug metabolism. J Pharm Pharmacol. 1994;46(Suppl 1):409-415.
15. Sandhu JS, Keating A, Hozumi N. Human gene therapy. Crit Rev Biotech. 1997;17(4):307-326.
16. Smith TJ. Gene therapy: Opportunities for pharmacy in the 21st century. Am J Pharmaceut Educ. 1996; 60:213-215.
17. Beauchamp TL, Childress JF. Principles of Biomedical Ethics. 4th ed. New York: Oxford University Press; 1994.
18. Kopala B. The Human Genome Project: Issues and ethics. Am J Maternal Child Nursing. 1997;22:9-12.
19. Blanck PD, Marti MW. Genetic discrimination and the employment provisions of the Americans with Disabilities Act: Emerging legal, empirical, and policy implications. Behavioral Sci Law. 1996;14:411-432.
20. Patenaude AF. The genetic testing of children for cancer susceptibility: Ethical, legal, and social issues. Behavioral Sci Law. 1996;14:393-410.
21. Wilfond BS, Noland K. National policy development for the clinical application of genetic diagnostic technologies. JAMA. 1993;270(24):2948-2954.
22. Cassel CK. Policy implications of the Human Genome Project for women. Women's Health Issues. 1997;7(4):225-229.
23. Mahowald MB, Levinson D, Cassel C, Lemke A, et al. The new genetics and women. Milbank Quarterly. 1996;74(2):239-283.
24. Nsiah-Jefferson L. Reproductive genetic services for low-income women and women of color: Access and sociocultural issue. In: Rothenberg KH, Thomsom EJ, eds. Women and Prenatal Testing: Facing the Challenges of Genetic Technology. Columbus, OH: Ohio State University Press; 1994.
25. Ravine D, Cooper DN. Adult-onset genetic disease: mechanisms, analysis and prediction. Q J Med. 1997; 90:83-103.
26. Salkovskis PM, Rimes KA. Predictive genetic testing: psychological factors. J Psychosomatic Res. 1997;43(5):477-487.
27. Scriver CR. We mean well: Treatment of Mendelian disease. Acta Paediatr Japonica. 1988;30:385-389.